We’re not just making subcutaneous injections possible.
We’re making them easy, too.
Up to 90+% of patients prefer subcutaneous injection…
Patient Preference and Adherence 2021:15 811–834
… but high-dose biologics become viscous, preventing injection.
CoFlo’s proprietary technology eliminates this injectability bottleneck, enabling 10-200x faster injection of viscous drug products
Validated with 6 marketed and clinical-stage drugs
CoFlo-Drug combination products can:
Transition intravenous therapies to subcutaneous
Reduce injection duration, injection volume, and needle size
Enable dual-drug administration
All with no change to the drug formulation and existing fill/finish
Press and Awards
Grand Prize Winner
